|
|
|
|
Дата |
|---|
| 13.05.2026 |
| 06.05.2026 |
| 28.04.2026 |
| 27.04.2026 |
| 23.04.2026 |
| 20.04.2026 |
| 16.04.2026 |
| 15.04.2026 |
| 13.04.2026 |
| 09.04.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
|
|
6.88
|
6.88
|
6.88
|
6.88
|
|
|
6.88
|
7.00
|
|
|
|
7.11
|
7.11
|
7.11
|
7.11
|
|
|
7.11
|
8.00
|
|
|
|
7.11
|
7.11
|
7.11
|
7.11
|
|
|
7.11
|
7.00
|
|
|
|
7.11
|
7.11
|
7.11
|
7.11
|
|
|
7.11
|
8.00
|
|
|
|
7.11
|
7.11
|
7.11
|
7.11
|
|
|
7.11
|
7.00
|
|
|
|
7.35
|
7.35
|
7.35
|
7.35
|
|
|
22.05
|
8.00
|
|
|
|
7.27
|
7.27
|
7.27
|
7.27
|
|
|
14.54
|
8.00
|
|
|
|
7.27
|
7.27
|
7.27
|
7.27
|
|
|
14.54
|
8.00
|
|
|
|
7.19
|
7.19
|
7.19
|
7.19
|
|
|
7.19
|
8.00
|
|
|
|
7.42
|
7.22
|
7.42
|
7.22
|
|
|
14.44
|
7.00
|
Lakefront Biotherapeutics NV is a Belgiumbased company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses dealmaking capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinicalstage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than inhouse cell therapy platforms. It builds a portfolio of clinicalstage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.
Американская биофармацевтическая компания Gilead Sciences купит права на использование результатов исследований и разработок у Galapagos NV, сообщается в пресс –релизе Gilead. Десятилетний контракт обойдется Gilead в $5,1 млрд. Сделка не...
| 07.05.2026 |
|
| 24.02.2026 |
|
| 06.11.2025 |
|
| 24.04.2025 |
|
| 13.02.2025 |
|